DUSSELDORF, Germany, May 12 /PRNewswire/ -- The rating agency Standard & Poor's has today confirmed the current rating of BB+ for the Gerresheimer Group and continues to categorize the outlook as stable. The focus of the MDAX company on the pharma & life science industry is therefore assessed as positive and sustainable by the rating agency.
About Gerresheimer
Gerresheimer employs around 10,000 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.
Contact Press
Burkhard Lingenberg
Director Corporate Communication & Marketing
Phone +49-211-6181-250
Fax +49-211-6181-241
e-mail b.lingenberg@gerresheimer.com
Contact Investor Relations
Anke Linnartz
Director Corporate Investor Relations
Phone +49-211-6181-314
Fax +49-211-6181-121
e-mail a.linnartz@gerresheimer.com
Contact Press: Burkhard Lingenberg, Director Corporate Communication & Marketing, Phone +49-211-6181-250, Fax +49-211-6181-241, e-mail b.lingenberg@gerresheimer.com. Contact Investor Relations: Anke Linnartz, Director Corporate Investor Relations, Phone +49-211-6181-314, Fax +49-211-6181-121, e-mail a.linnartz@gerresheimer.com